+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fibromyalgia Therapeutics Market by Drug Class (Anticonvulsants, Selective Serotonin Reuptake Inhibitors, Serotonin and Norepinephrine Reuptake Inhibitors), Route Of Administration (Oral, Parenteral, Topical), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Fibromyalgia Therapeutics Market by Drug Class (Anticonvulsants, Selective Serotonin Reuptake Inhibitors, Serotonin and Norepinephrine Reuptake Inhibitors), Route Of Administration (Oral, Parenteral, Topical), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Fibromyalgia Therapeutics Market by Drug Class (Anticonvulsants, Selective Serotonin Reuptake Inhibitors, Serotonin and Norepinephrine Reuptake Inhibitors), Route Of Administration (Oral, Parenteral, Topical), Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887861
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The fibromyalgia therapeutics market is undergoing rapid transformation, driven by advancements in personalized medicine, innovative therapies, and evolving care models. Decision-makers seeking to outpace competitors and address unmet needs must understand the shifting landscape, emerging technologies, and region-specific opportunities that are shaping the trajectory of fibromyalgia treatment.

Market Snapshot: Fibromyalgia Therapeutics Market Growth and Dynamics

The Fibromyalgia Therapeutics Market is experiencing steady growth, with expansion supported by a robust pipeline, increased adoption of targeted treatments, and heightened investment in research and development. The market is influenced by factors such as rising disease prevalence, the emergence of novel non-opioid therapies, and greater focus on digital health solutions. Growth trends reflect strong demand across key regions, ongoing product innovation, and an adaptive regulatory environment.

Scope & Segmentation

  • Drug Classes: Anticonvulsants (branded, generic); Selective Serotonin Reuptake Inhibitors (branded, generic); Serotonin and Norepinephrine Reuptake Inhibitors (branded, generic); Tricyclic Antidepressants (branded, generic).
  • Routes of Administration: Oral, parenteral, topical.
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy.
  • End Users: Home care, hospital, specialty clinics.
  • Regions Covered: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies Profiled: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited.

Key Takeaways for Decision-Makers

  • Multidisciplinary models integrating digital health solutions, behavioral therapy, and patient education are changing traditional treatment approaches and enhancing long-term outcomes for fibromyalgia patients.
  • Therapy development is increasingly guided by scientific advances in neurobiology, gene expression profiling, and identification of patient subgroups most likely to respond to specific treatments, supporting precision medicine initiatives.
  • Regulatory agencies are adopting flexible frameworks that value real-world evidence and patient-centered endpoints, enabling accelerated market access for innovative therapies.
  • Growth in the non-opioid and adjunctive digital therapeutics segments is responding to heightened scrutiny of traditional pain management options and growing concerns around safety and side effect profiles.
  • Major players are leveraging co-development partnerships, advanced process engineering, and expanded R&D to address geographic gaps and introduce pioneering mechanism-based treatments.
  • Regional strategies remain essential, as healthcare financing, regulatory stringency, and access to innovative therapeutics differ considerably among Americas, EMEA, and Asia-Pacific markets.

Tariff Impact on Fibromyalgia Therapeutics Supply Chains

Recent United States tariff policies have raised procurement costs for core pharmaceutical ingredients, prompting manufacturers to restructure supply chains and invest in onshore synthesis. These shifts are reshaping approaches to contract manufacturing, sourcing agreements, and technology transfer, adding layers of complexity to operations. Industry stakeholders are actively seeking collaborative policy solutions to safeguard uninterrupted access to critical therapies for fibromyalgia within a changing global trade environment.

Methodology & Data Sources

This report is grounded in interviews with neurologists, rheumatologists, pain specialists, and pharmacoeconomists, complemented by pharmacist and healthcare administrator surveys. A rigorous review of peer-reviewed literature, regulatory bulletins, clinical trial registries, and health authority guidelines underpins the analysis. Data triangulation and external expert review ensure credibility and actionable relevance throughout.

Why This Report Matters

  • Enables executive decision-makers to identify high-impact investment and partnership opportunities grounded in the latest market trends and regulatory changes.
  • Supports strategy development by providing granular segmentation analysis, allowing for targeted approaches in product positioning, regional expansion, supply chain resilience, and stakeholder engagement.

Conclusion

The fibromyalgia therapeutics sector is advancing through innovation, integration of digital health, and resilient operational models. Strategic alignment with emerging care paradigms and supply chain adaptation will be key for stakeholders aiming to drive positive patient and business outcomes in this evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of wearable biosensors and mobile apps for continuous fibromyalgia pain monitoring and management
5.2. Emergence of monoclonal antibody therapies targeting fibromyalgia central sensitization pathways
5.3. Development of non-opioid neuromodulation devices for chronic fibromyalgia pain relief in outpatient settings
5.4. Increased investment in CRISPR-based gene editing research to modulate fibromyalgia pain signaling pathways
5.5. Growing adoption of virtual reality cognitive behavioral therapy interventions to reduce fibromyalgia symptom burden
5.6. Expansion of combination regimens pairing SNRIs with cannabinoid-derived compounds for enhanced fibromyalgia management
5.7. Advancements in gut microbiome modulation therapies as a novel treatment avenue for fibromyalgia-associated fatigue
5.8. Regulatory shifts enabling accelerated approval pathways for personalized peptide-based fibromyalgia therapeutics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Fibromyalgia Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Anticonvulsants
8.2.1. Branded
8.2.2. Generic
8.3. Selective Serotonin Reuptake Inhibitors
8.3.1. Branded
8.3.2. Generic
8.4. Serotonin And Norepinephrine Reuptake Inhibitors
8.4.1. Branded
8.4.2. Generic
8.5. Tricyclic Antidepressants
8.5.1. Branded
8.5.2. Generic
9. Fibromyalgia Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.4. Topical
10. Fibromyalgia Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Fibromyalgia Therapeutics Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospital
11.4. Specialty Clinics
12. Americas Fibromyalgia Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Fibromyalgia Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Fibromyalgia Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Eli Lilly and Company
15.3.3. AbbVie Inc.
15.3.4. Teva Pharmaceutical Industries Ltd.
15.3.5. Viatris Inc.
15.3.6. Sandoz International GmbH
15.3.7. Sun Pharmaceutical Industries Ltd.
15.3.8. Torrent Pharmaceuticals Ltd.
15.3.9. Dr. Reddy's Laboratories Ltd.
15.3.10. Cipla Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. FIBROMYALGIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. FIBROMYALGIA THERAPEUTICS MARKET: RESEARCHAI
FIGURE 24. FIBROMYALGIA THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 25. FIBROMYALGIA THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 26. FIBROMYALGIA THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. FIBROMYALGIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 106. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 107. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 110. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 111. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 112. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 113. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 252. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 253. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 258. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 259. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. U

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Fibromyalgia Therapeutics market report include:
  • Pfizer Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.91 Billion
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Fibromyalgia Therapeutics - Global Strategic Business Report - Product Image

Fibromyalgia Therapeutics - Global Strategic Business Report

  • Report
  • 263 Pages
  • Global
From
Fibromyalgia Treatment - Global Strategic Business Report - Product Image

Fibromyalgia Treatment - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Fibromyalgia - Pipeline Insight, 2025 - Product Image

Fibromyalgia - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Fibromyalgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Fibromyalgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
From
Fibromyalgia Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Fibromyalgia Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 135 Pages
  • Global
From

About the Fibromyalgia Drug Market

The Fibromyalgia Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Fibromyalgia drugs are used to reduce pain, improve sleep, and reduce fatigue. Commonly prescribed drugs include antidepressants, anticonvulsants, and muscle relaxants. Other treatments include physical therapy, cognitive behavioral therapy, and lifestyle modifications. The Fibromyalgia Drug market is highly competitive, with a number of companies offering treatments. Some of the major players in the market include Pfizer, Eli Lilly, Merck, and Novartis. Other companies include AbbVie, Allergan, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.